Skip to main content

Table 2 Tacrolimus dosing pre- and 12 months post-conversion comparison by genotype: expressers (*1/*1 + *1/*3) and non-expressers (*3/*3)

From: The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients

Variable *1/*1 and *1/*3 *3/*3 p value
N = 17 N = 43
Required Tac dose increase (%) 10 (59) 20 (47) 0.004
Tac BID (mg/day) 4.6 ± 2.7 2.4 ± 1.2 0.0003
Tac OD (mg/day) 6 ± 2.7 2.9 ± 1.2 0.0001
Tac dose adjustment from BID to OD (%) 45.3 ± 48.3 26.6 ± 32.1 0.003
  1. BID twice daily, OD once daily, Tac tacrolimus
  2. *1/*3 expressers; *3/*3 non-expressers